

# Lisa M Rimsza

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7788019/publications.pdf>

Version: 2024-02-01

67  
papers

6,930  
citations

236925

25  
h-index

144013

57  
g-index

67  
all docs

67  
docs citations

67  
times ranked

8700  
citing authors

#	ARTICLE	IF	CITATIONS
1	Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. <i>Nature</i> , 2011, 476, 298-303.	27.8	1,428
2	Molecular Diagnosis of Burkitt's Lymphoma. <i>New England Journal of Medicine</i> , 2006, 354, 2431-2442.	27.0	824
3	Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. <i>Journal of Clinical Oncology</i> , 2012, 30, 3452-3459.	1.6	824
4	Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. <i>Nature</i> , 2012, 490, 116-120.	27.8	759
5	Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. <i>Blood</i> , 2014, 123, 1214-1217.	1.4	518
6	Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. <i>Journal of Clinical Oncology</i> , 2015, 33, 2848-2856.	1.6	334
7	Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. <i>Blood</i> , 2004, 103, 4251-4258.	1.4	296
8	A multiprotein supercomplex controlling oncogenic signalling in lymphoma. <i>Nature</i> , 2018, 560, 387-391.	27.8	276
9	US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. <i>Journal of Clinical Oncology</i> , 2016, 34, 2020-2027.	1.6	239
10	Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus <sup>131</sup> Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016. <i>Journal of Clinical Oncology</i> , 2013, 31, 314-320.	1.6	152
11	Reproducing the molecular subclassification of peripheral T-cell lymphoma by immunohistochemistry. <i>Blood</i> , 2019, 134, 2159-2170.	1.4	120
12	New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. <i>Journal of Clinical Oncology</i> , 2017, 35, 1668-1677.	1.6	102
13	A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. <i>Blood</i> , 2018, 132, 413-422.	1.4	89
14	Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2010, 95, 597-603.	3.5	87
15	Distinct molecular profile of IRF4-rearranged large B-cell lymphoma. <i>Blood</i> , 2020, 135, 274-286.	1.4	81
16	Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. <i>Journal of Clinical Oncology</i> , 2020, 38, 3003-3011.	1.6	75
17	Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus <sup>131</sup> I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. <i>Journal of Clinical Oncology</i> , 2018, 36, 697-703.	1.6	68
18	Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. <i>Blood</i> , 2018, 132, 2401-2405.	1.4	64

#	ARTICLE	IF	CITATIONS
19	Histiocytic and dendritic cell neoplasms: what have we learnt by studying 67 cases. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 467-489.	2.8	59
20	Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma. <i>Laboratory Investigation</i> , 2007, 87, 979-997.	3.7	50
21	MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma. <i>Haematologica</i> , 2021, 106, 2682-2693.	3.5	44
22	Neonatal expression of RNA-binding protein IGF2BP3 regulates the human fetal-adult megakaryocyte transition. <i>Journal of Clinical Investigation</i> , 2017, 127, 2365-2377.	8.2	39
23	Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016. <i>Blood</i> , 2019, 133, 81-93.	1.4	34
24	A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOPâ€“Rituximab versus CHOP + 131Iodineâ€“Tositumomab. <i>Clinical Cancer Research</i> , 2013, 19, 6624-6632.	7.0	32
25	The clinicopathologic spectrum of mature aggressive B cell lymphomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 453-466.	2.8	27
26	Validation of the <sc>MCL</sc>35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network. <i>British Journal of Haematology</i> , 2019, 184, 616-624.	2.5	25
27	The <sc>MCL</sc>35 gene expression proliferation assay predicts highâ€“risk <sc>MCL</sc> patients in a Norwegian cohort of younger patients given intensive first line therapy. <i>British Journal of Haematology</i> , 2018, 183, 225-234.	2.5	24
28	Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2019, 9, 48.	6.2	24
29	Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort. <i>Haematologica</i> , 2018, 103, e151-e153.	3.5	22
30	Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma. <i>Blood Advances</i> , 2019, 3, 3132-3135.	5.2	18
31	Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 6039-6053.	7.0	17
32	Enhanced DNA repair and genomic stability identify a novel HIVâ€“related diffuse large Bâ€“cell lymphoma signature. <i>International Journal of Cancer</i> , 2019, 145, 3078-3088.	5.1	16
33	Genomics of aggressive B-cell lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 69-74.	2.5	15
34	Recommendations for Tissue Microarray Construction and Quality Assurance. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 325-330.	1.2	15
35	Incorporation of digital gene expression profiling for cell-of-origin determination (Lymph2Cx testing) into the routine work-up of diffuse large B cell lymphoma. <i>Journal of Hematopathology</i> , 2019, 12, 3-10.	0.4	14
36	Activation-induced cytidine deaminase localizes to G-quadruplex motifs at mutation hotspots in lymphoma. <i>NAR Cancer</i> , 2020, 2, zcaa029.	3.1	14

#	ARTICLE	IF	CITATIONS
37	EBVâ€positive HIVâ€associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features. <i>British Journal of Haematology</i> , 2021, 194, 870-878.	2.5	14
38	Benign B-Cell Precursors (Hematogones) Are the Predominant Lymphoid Population in the Bone Marrow of Preterm Infants. <i>Neonatology</i> , 2004, 86, 247-253.	2.0	13
39	A Cyclin D1â€Dependent Transcriptional Program Predicts Clinical Outcome in Mantle Cell Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 213-225.	7.0	10
40	Langerhans cell histiocytosis shows distinct cytoplasmic expression of major histocompatibility class II antigens. <i>Journal of Hematopathology</i> , 2016, 9, 107-112.	0.4	9
41	Clinical laboratory validation of the MCL35 assay for molecular risk stratification of mantle cell lymphoma. <i>Journal of Hematopathology</i> , 2020, 13, 231-238.	0.4	7
42	Primary Pulmonary B-cell Lymphoma. <i>Seminars in Diagnostic Pathology</i> , 2020, 37, 259-267.	1.5	6
43	B-cell lymphomas with discordance between pathological features and clinical behavior. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 439-451.	2.8	5
44	Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 113-117.	2.8	5
45	Genetic heterogeneity highlighted by differential FDG-PET response in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2020, 105, 318-321.	3.5	5
46	Lenalidomide Combined with R-CHOP (R2CHOP) Overcomes Negative Prognostic Impact of ABC Molecular Subtype in Newly Diagnosed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 3035-3035.	1.4	5
47	Profiling of lymphoma from formalin-fixed paraffin-embedded tissue. <i>Seminars in Hematology</i> , 2019, 56, 46-51.	3.4	4
48	Clinical features and cell of origin subtyping using gene expression profiling in HIV-negative patients with primary central nervous system lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 3581-3583.	1.3	4
49	Continued Excellent Outcomes in Previously Untreated Follicular Lymphoma Patients after Treatment with CHOP Plus Rituximab or CHOP Plus (131) Iodine-Tositumomab - Long Term Follow-up of Phase III Randomized Study SWOG S0016. <i>Blood</i> , 2016, 128, 616-616.	1.4	3
50	General Biomarker Recommendations for Lymphoma. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw250.	6.3	2
51	Dissecting aggressive B-cell lymphoma through genomic analysis â€ What is clinically relevant?. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 187-198.	1.7	2
52	Frequent expression of activation-induced cytidine deaminase in diffuse large B-cell lymphoma tissues from persons living with HIV. <i>Aids</i> , 2020, 34, 2025-2035.	2.2	2
53	Assessment of 2-Year Storage Conditions on Protein, RNA, and DNA in Unstained Human Tissue Sections, Including a Novel Multiplex Digital Gene Expression Profiling Method with Implications for Biobanking. <i>Biopreservation and Biobanking</i> , 2022, 20, 473-484.	1.0	2
54	Over-Expression of Transferrin Receptor (TFRC/CD71) and Low Expression of Innate and Adaptive Immune Cell Subsets in HIV-Associated, GCB-DLBCL By Digital Gene Expression Profiling. <i>Blood</i> , 2019, 134, 2783-2783.	1.4	2

#	ARTICLE	IF	CITATIONS
55	Mediastinal B-cell lymphoma with MYC, BCL2, and BCL6 rearrangements. <i>Journal of Hematopathology</i> , 2022, 15, 151-155.	0.4	2
56	Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816. <i>Leukemia and Lymphoma</i> , 2020, 61, 2442-2447.	1.3	1
57	Clinical Validation of MCL35 in Mantle Cell Lymphoma Patients ≥65 Years Receiving Bendamustine-Rituximab. <i>Blood</i> , 2021, 138, 3517-3517.	1.4	1
58	Transcriptional profiles define drug refractory disease in myeloma. <i>EJHaem</i> , 2022, 3, 804-814.	1.0	1
59	Concurrent Targeting of BCL2 and MYC Transcription Leads to Chemo-Sensitization of Dual-Expressing Diffuse Large B-Cell Lymphoma In Vivo. <i>Blood</i> , 2016, 128, 4090-4090.	1.4	0
60	Whole-Exome Analysis Reveals Novel Somatic Genomic Alterations Associated with Cell of Origin in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 2935-2935.	1.4	0
61	Autologous Transplantation As Consolidation for High Risk Aggressive T-Cell Non-Hodgkin's Lymphoma: A SWOG S9704 Intergroup Trial Subgroup Analysis. <i>Blood</i> , 2016, 128, 4651-4651.	1.4	0
62	Enhanced DNA Repair and Genomic Stability in HIV(+) Diffuse Large B Cell Lymphoma of Germinal Center Origin. <i>Blood</i> , 2018, 132, 1570-1570.	1.4	0
63	Enhanced Expression of FGF Signaling in Primary Central Nervous System Lymphoma. <i>Blood</i> , 2018, 132, 2847-2847.	1.4	0
64	Five-Year Outcomes of SWOG S1106: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2018, 132, 1593-1593.	1.4	0
65	Longitudinal Analyses of Diagnostic-Relapse Biopsies of Diffuse Large B Cell Lymphoma Reveal a Poor Risk Subset of ABC Patients Based on the Expression of a 30 Gene Panel. <i>Blood</i> , 2019, 134, 2769-2769.	1.4	0
66	Transformation of Follicular Lymphoma into Primary Mediastinal B-Cell Lymphoma-like Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 4479-4479.	1.4	0
67	Global Transcriptional States of Follicular Lymphoma B Cells Highlight Distinct Groups of Tumor Identity Associated with Somatic Alterations and Tumor Microenvironment. <i>Blood</i> , 2020, 136, 21-22.	1.4	0